Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea® in Subjects With Neovascular Age-related Macular Degeneration

NCT04480463 is registered in ClinicalTrials.gov with Sam Chun Dang Pharm. Co. Ltd. as lead sponsor.

NCT NCT04480463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea® in Subjects With Neovascular Age-related Macular Degeneration
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 13, 2020
Completion date
September 8, 2022
Enrollment
576 (actual)
Sites
130

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration, wet age-related macular degeneration